natgillin/translations-raw huggingface dataset:
The pump must not be implanted in people who reside permanently at elevations above at elevations above 2,439 metres (8000 feet). 
Črpalka se ne sme vsaditi pri ljudeh, ki stalno prebivajo na nadmorski višini nad 2 439 metrov (8000 čevljev).
The full EPAR for Insuman can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Insuman je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Insuman should be given before meals. 
Zdravilo Insuman je treba dajati pred obrokom.
Insuman human insulin 
Insuman humani insulin
What benefit has Insuman shown during the studies? 
Kakšne koristi je zdravilo Insuman izkazalo med študijami?
The injection site is changed for each injection. 
Mesto injiciranja je treba pri vsaki injekciji spremeniti.
This is a summary of the European public assessment report (EPAR) for Insuman. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Insuman.
No other insulins must be used with the pump and the pump must not be used in children who have not yet reached adult size. 
S črpalko se ne sme uporabiti nobenega drugega insulina, črpalka pa se ne sme uporabiti pri otrocih, ki še niso dosegli velikosti odraslih.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Insuman. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Insuman, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The Insuman range is comprised of: 
Izdelki Insuman vključujejo:
Insuman Rapid may also be given into a vein, but only in an intensive care unit or similar setting where the patient can be closely monitored. 
Zdravilo Insuman Rapid se lahko daje tudi v veno, vendar le na oddelku za intenzivno nego ali v podobnem okolju, kjer je mogoče bolnika natančno nadzorovati.
By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced. 
Z uravnavanjem ravni glukoze v krvi se simptomi in zapleti, povezani s sladkorno boleznijo, zmanjšajo.
Other information about Insuman 
Druge informacije o zdravilu Insuman
What is the risk associated with Insuman? 
Kakšna tveganja so povezana z zdravilom Insuman?
It must also not be used in patients who are hypersensitive to titanium alloy, polysulfone or silicone material used in the components of the implanted pump. 
Prav tako se ne sme uporabljati pri bolnikih, ki so preobčutljivi za titanovo zlitino, polisulfonske ali silikonske materiale, uporabljene v sestavnih delih vsajene črpalke.
The main measure of effectiveness in all studies was the change in the level of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood that has glucose attached. 
Glavno merilo učinkovitosti v vseh študijah je bila sprememba ravni glikoziliranega hemoglobina (HbA1c), kar je odstotek hemoglobina v krvi, na katerega je vezana glukoza.
For more information about treatment with Insuman, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Insuman preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Insuman may cause hypoglycaemia. 
Zdravilo Insuman lahko povzroči hipoglikemijo.
Insuman must not be used in people who are hypersensitive (allergic) to human insulin or any of the other ingredients. 
Zdravila Insuman ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) humani insulin ali katero koli drugo sestavino zdravila.
See the package leaflet for exact timings. 
Za natančen čas dajanja glejte navodilo za uporabo.
Why has Insuman been approved? 
Zakaj je bilo zdravilo Insuman odobreno?
The active substance in Insuman, human insulin, is produced by a method known as ‘recombinant DNA technology': it is made by bacteria into which a gene (DNA) has been introduced that makes the bacteria able to produce insulin. 
Zdravilna učinkovina zdravila Insuman, humani insulin, se proizvaja z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri se v bakterije vstavi gen (DNK), s katerim lahko tvorijo insulin.
The replacement insulin acts in the same way as naturally produced insulin and helps glucose enter cells from the blood. 
Nadomestni insulin deluje enako kot naravno proizvedeni insulin in omogoča, da lahko glukoza iz krvi preide v celice.
The Committee recommended that Insuman be given marketing authorisation. 
Priporočil je, da se za zdravilo Insuman odobri dovoljenje za promet.
• Insuman Comb, which is available in various combinations of fast- and intermediate-acting insulins. 
• Insuman Comb, ki je na voljo v različnih kombinacijah insulina s hitrim in srednje dolgim delovanjem.
Insuman is used in patients with diabetes (type 1 and 2) who need treatment with insulin. 
Zdravilo Insuman se uporablja pri bolnikih s sladkorno boleznijo (tipa 1 in tipa 2), ki potrebujejo zdravljenje z insulinom.
Insuman contains insulin in various forms: the soluble form, which acts quickly (within 30 minutes of injection), and the isophane and crystalline-protamine forms, which are absorbed much more slowly during the day, giving them a longer duration of action. 
Zdravilo Insuman vsebuje insulin v različnih oblikah: v topni obliki, ki učinkuje hitro (v 30 minutah po injiciranju), ter v „izofani“ in kristalni obliki s protaminom, ki se absorbira veliko počasneje v teku dneva ter posledično zagotavlja daljše trajanje učinkovanja.
Diabetes is a disease in which the body does not produce enough insulin to control the level of blood glucose (type 1 diabetes) or when the body is unable to use insulin effectively (type 2 diabetes). 
Sladkorna bolezen je bolezen, pri kateri telo ne proizvaja dovolj insulina za vzdrževanje primerne ravni glukoze v krvi (sladkorna bolezen tipa 1) ali pri kateri telo insulina ne more učinkovito uporabljati (sladkorna bolezen tipa 2).
Further information on the way Insuman is given can be found in the Summary of Product Characteristics (also part of the EPAR). 
Za dodatne informacije o načinu dajanja zdravila Insuman glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
These patients received Insuman Implantable as a continuous infusion into the peritoneal cavity. 
Bolniki so zdravilo Insuman Implantable prejemali kot kontinuirano infuzijo v peritonealno votlino.
Insuman has been studied in three trials in 780 patients with either type 1 diabetes or type 2 diabetes. 
Zdravilo Insuman so proučevali v treh študijah s 780 bolniki s sladkorno boleznijo tipa 1 ali tipa 2.
Insuman Implantable is used in adult patients with type 1 diabetes that cannot be controlled with insulin given under the skin and who often have episodes of, otherwise unexplained, hyper- or hypoglycaemia (high or low blood glucose levels). 
Zdravilo Insuman Implantable se uporablja pri odraslih bolnikih s sladkorno boleznijo tipa 1, ki ga ni mogoče urediti z insulinom, danim pod kožo, in ki imajo pogosto epizode drugače nepojasnjene hiperali hipoglikemije (visoke ali nizke ravni glukoze v krvi).
Insuman Rapid, Infusat, Basal and Comb are given by injection under the skin, generally in the abdominal wall (tummy) or the thigh, according to the doctor's recommendations. 
Zdravila Insuman Rapid, Infusat, Basal in Comb se dajejo z injekcijo pod kožo, običajno v trebušno steno ali stegno v skladu s priporočilom zdravnika.
Insuman Infusat is specially prepared ready to be used as a continuous infusion under the skin using an external portable infusion pump. 
Zdravilo Insuman Infusat je posebej pripravljeno za uporabo kot kontinuirana infuzija pod kožo z uporabo zunanje prenosne infuzijske črpalke.
Insuman is a replacement insulin that is similar to the insulin made by the body. 
Zdravilo Insuman je nadomestni insulin, ki je podoben insulinu, ki ga proizvaja telo.
In addition, Insuman Implantable was studied in adult patients with type 1 diabetes. 
Poleg tega so zdravilo Insuman Implantable proučevali pri odraslih bolnikih s sladkorno boleznijo tipa 1.
For the full list of all side effects reported with Insuman, see the Package Leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Insuman, glejte navodilo za uporabo.
Insuman Rapid can also be used for the treatment of hyperglycaemic coma (coma caused by too much blood glucose [sugar]) and ketoacidosis (high levels of ketones [acids] in the blood), and to control blood glucose before, during or after an operation. 
Zdravilo Insuman Rapid je primerno tudi za zdravljenje hiperglikemične kome (kome, pogojene s previsoko koncentracijo glukoze [sladkorja] v krvi) in ketoacidoze (visoke ravni ketonov [kislin] v krvi) ter za uravnavanje glukoze v krvi pred in med operacijo ter po njej.
The desired blood glucose levels, the type of Insuman to be used, and the dose and timing of injections are determined by the doctor for each patient individually, and are adjusted to suit the patient's diet, physical activity and lifestyle. 
Zdravnik za vsakega posameznika posebej določi zaželene koncentracije glukoze v krvi, vrsto zdravila Insuman, ki ga je treba uporabiti ter odmerek in čas uporabe injekcij ter jih prilagodi, da najbolje ustrezajo prehrani, telesni aktivnosti in življenjskemu slogu bolnika.
In one of the studies, Insuman was given to patients with type 1 diabetes using an external insulin pump. 
V eni od študij so zdravilo Insuman dajali bolnikom s sladkorno boleznijo tipa 1 z uporabo zunanje insulinske črpalke.
Insuman Implantable is given only by infusion into the abdominal cavity using a pump (Medtronic MiniMed implantable pump) that is implanted under the skin of the abdomen. 
Zdravilo Insuman Implantable se daje le z infundiranjem v trebušno votlino z uporabo črpalke (vsajene črpalke Medtronic MiniMed), ki je vsajena pod kožo trebuha.
• Insuman Rapid, Insuman Infusat and Insuman Implantable, which are fast-acting insulin solutions containing soluble insulin; 
• Insuman Rapid, Insuman Infusat in Insuman Implantable, tj. raztopine insulinov s hitrim delovanjem, ki vsebujejo topni insulin;
Insuman Implantable must not be used in any other way and can only be used in centres where staff have received adequate training in the use of the implantable pump. 
Uporablja se lahko le na ta način in to le v centrih, kjer so zaposleni ustrezno usposobljeni za uporabo vsajene črpalke.
Insuman led to a decrease in the level of HbA1c, indicating that blood glucose levels had been controlled to a similar level to that seen with semi-synthetic human insulin. 
Zdravilo Insuman je privedlo do znižanja koncentracije HbA1c, kar kaže, da so bile koncentracije glukoze v krvi vzdrževane na podobni ravni kot pri polsintetičnem humanem insulinu.
The CHMP decided that Insuman's benefits are greater than its risks for the treatment of type 1 and type 2 diabetes. 
CHMP je zaključil, da so koristi zdravila Insuman pri zdravljenju sladkorne bolezni tipa 1 in tipa 2 večje od z njim povezanih tveganj.
• Insuman Basal, an intermediate-acting insulin suspension containing isophane insulin; 
• Insuman Basal, suspenzijo insulinov s srednje dolgim delovanjem, ki vsebuje insulin izofan;
What is Insuman used for? 
Za kaj se zdravilo Insuman uporablja?
The patient's blood glucose should be tested regularly to find the lowest effective dose. 
Za določitev najmanjšega učinkovitega odmerka je potrebno redno spremljati koncentracijo glukoze v krvi bolnika.
Insuman is a range of insulin-containing solutions and suspensions for injection. 
Zdravilo Insuman obsega različne raztopine in suspenzije za injiciranje, ki vsebujejo insulin.
How does Insuman work? 
Kako zdravilo Insuman deluje?
In addition, Insuman Implantable must not be used any other way than as a continuous infusion using the Medtronic MiniMed Implantable Pump. 
Pole tega se zdravilo Insuman Implantable lahko uporablja le kot kontinuirana infuzija z uporabo vsajene črpalke Medtronic MiniMed.
In another study, Insuman Comb 25 was compared with semi-synthetic human insulin in patients with type 1 and type 2 diabetes. 
V drugi pa so zdravilo Insuman Comb 25 pri bolnikih s sladkorno boleznijo tipa 1 in tipa 2 primerjali s polsintetičnim humanim insulinom.
It is supplied in vials, cartridges, or pre-filled disposable pens. 
Na voljo je v vialah, injekcijskih vložkih ali napolnjenih injekcijskih peresnikih za enkratno uporabo.
How is Insuman used? 
Kako se zdravilo Insuman uporablja?
What is Insuman? 
Kaj je zdravilo Insuman?
Insuman was effective for both type 1 and type 2 diabetes. 
Zdravilo Insuman je bilo učinkovito tako pri sladkorni bolezni tipa 1 kot tipa 2.
How has Insuman been studied? 
Kako je bilo zdravilo Insuman raziskano?
Data show that immune tolerance may be achieved. 
Podatki kažejo, da se imunska toleranca lahko doseže.
However, in some cases, especially in younger patients, more frequent injections or higher doses may be necessary. 
Vendar pa so v nekaterih primerih, še posebej pri mlajših bolnikih, lahko potrebne pogostejše injekcije ali večji odmerki.
Tel: +44(0)1256 894 959 e-mail: medinfoEMEA@shire.com 
Tel: +44(0)1256 894 959 e-pošta: medinfoEMEA@shire.com
Wash your hands thoroughly using soap and warm water. 
Temeljito si umijte roke z milom in toplo vodo.
This is particularly important if you are having major surgery. 
To je še posebej pomembno pri večjih operacijah.
The product dissolves rapidly (usually in less than 1 minute). 
Prašek se hitro raztaplja (ponavadi prej kot v 1 minuti).
Important note: 
Pomembno opozorilo:
This product is for single use only. 
Ta izdelek je samo za enkratno uporabo.
Frequency of doses (hours)/duration of therapy (days) 
Pogostnost odmerjanja (ure)/Trajanje zdravljenja (dni)
Parameter (mean ± standard deviation) 
Parameter (srednja vrednost ± standardni odklon)
ATC code: B02BD02. 
Oznaka ATC: B02BD02
Additional side effects in children 
Dodatni neželeni učinki pri otrocih
Date of latest renewal: 20 December 2013 
Datum prve odobritve: 2. marec 2004 Datum zadnjega podaljšanja: 20. december 2013
Frequency categories are defined according to the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the available data). 
Kategorije pogostnosti so opredeljene v skladu z naslednjim dogovorom: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1000 do < 1/100), redki (≥ 1/10.000 do < 1/1000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
However, chemical and physical in-use stability has been demonstrated for 3 hours at 25 °C. 
Kemično in fizikalno stabilnost zdravila med uporabo so sicer dokazali za čas 3 ur pri temperaturi 25 °C.
The data from this study demonstrate that the two prophylactic dosing regimens are comparable in terms of reduction of bleeding rate. 
Podatki iz te študije kažejo, da je pri obeh režimih preventivnega odmerjanja zmanjšanje hitrosti krvavitve primerljivo.
- Use within three hours after reconstitution. 
- Uporabite v treh urah po rekonstituciji.
ANNEX II A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
PRILOGA II A. IZDELOVALCI BIOLOŠKE ZDRAVILNE UČINKOVINE IN IZDELOVALEC, ODGOVOREN ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
Use immediately or within 3 hours of reconstitution. 
Po rekonstituciji uporabite takoj ali v 3 urah.
A non-interventional prospective registry (PASS-INT-004) documented ITI in 44 paediatric and adult subjects of whom 36 completed ITI therapy. 
V neintervencijskem prospektivnem registru (PASS-INT-004) se je ITI zabeležil pri 44 pediatričnih in odraslih preiskovancih, od tega jih je 36 zaključilo zdravljenje ITI.
Do not draw air into the syringe. 
Pri tem ne smete posesati zraka v brizgo.
Catheter-related complications in treatment 
S katetri povezani zapleti zdravljenja
In case of shock, standard medical treatment for shock should be implemented. 
V primeru šoka uvedite standardno medicinsko zdravljenje za zdravljenje šoka.
The safety and haemostatic efficacy of ADVATE in the paediatric population are similar to that of adult patients. 
Varnost in hemostatska učinkovitost zdravila ADVATE pri pediatrični populaciji sta podobni kot pri odraslih bolnikih.
The dose and frequency of administration should be adapted to the clinical response in the individual case. 
Odmerek in pogostnost dajanja zdravila morata biti prilagojena kliničnemu odzivu v posameznem primeru.
Rarely, inhibitors may develop after the first 100 exposure days. 
Le redko pa zaviralci nastanejo po prvih 100 dnevih izpostavljenosti.
If such inhibitors occur, the condition will manifest itself as an insufficient clinical response. 
Pri nastanku teh zaviralcev se stanje kaže kot nezadosten klinični odziv.
You should tell your doctor if you have been previously treated with Factor VIII products, especially if you developed inhibitors, since there might be a higher risk that it happens again. 
Zdravniku morate povedati, če ste bili že kdaj prej zdravljeni s pripravki faktorja VIII, še posebej, če so se pri vas pojavili zaviralci, ker lahko v tem primeru obstaja povečano tveganje, da se bo to spet zgodilo.
ADVATE is indicated in all age groups. 
Zdravilo ADVATE je indicirano za vse starostne skupine.
Within a sub-study of PUP-study 060103, ITI-treatments in 11 PUPs were documented. 
V okviru podštudije študije PUP 060103 so opisali zdravljenje ITI pri 11 PUP.
Prepared without the addition of any (exogenous) human- or animal-derived protein in the cell culture process, purification or final formulation. 
Pripravljeno brez dodajanja kakršnihkoli (eksogenih) beljakovin človeškega ali živalskega izvora pri postopku celične kulture, prečiščevanja ali končne formulacije zdravila.
Should a significant increase occur, reducing the rate of administration or temporarily interrupting the injection usually allows the symptoms to disappear promptly (see sections 4.4 and 4.8). 
Če pride do znatnega povečanja pulza, lahko z zmanjšanjem hitrosti infuzije oziroma z začasno prekinitvijo injiciranja običajno dosežemo takojšnje izginotje simptomov (glejte poglavji 4.4 in 4.8).
Detailed instructions for self-administration are given at the end of this package leaflet. 
Podrobna navodila za samoinjiciranje zdravila so podana ob koncu teh navodil.
The analysis of plasma samples was conducted in a central laboratory using a one-stage clotting assay. 
Analiza vzorcev plazme je bila opravljena v enem centralnem laboratoriju z uporabo enostopenjskega strjevalnega testa.
Baxalta Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Switzerland 
Baxalta Manufacturing Sàrl Route de Pierre-à-Bot 111 CH-2000 Neuchâtel Švica
It is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. 
Izdelan je s tehnologijo rekombinantne DNA v ovarijskih celicah kitajskega hrčka (CHO).
Categories of these analyses for infants (1 month to <2 years of age), children (2 to <5 years of age), older children (5 to <12 years of age), adolescents (12 to <18 years of age), and adults (18 years of age and older) were used to summarize PK parameters, where age was defined as age at time of PK infusion. 
Kategorije teh analiz za dojenčke (stare od 1 meseca do < 2 let), otroke (stare od 2 do < 5 let), starejše otroke (stare od 5 do < 12 let), mladostnike (stare od 12 do < 18 let) in odrasle (stare 18 let in več) so bile uporabljene za oblikovanje povzetka farmakokinetičnih parametrov, kjer je bila starost opredeljena kot starost v času farmakokinetične infuzije.
The required dose is determined using the following formula: 
Potrebni odmerek določimo z uporabo naslednje enačbe:
After reconstitution, the solution is clear, colourless, free from foreign particles and has a pH of 6.7 to 7.3. 
Po rekonstituciji je raztopina bistra in brezbarvna, brez tujih delcev in ima pH od 6,7 do 7,3.
C OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION 
C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM
Factor VIII level required (% or IU/dl) 
Potrebna koncentracija faktorja VIII (% ali i.e./dl)
Place the vials on a flat clean surface. 
Viale postavite na ravno čisto površino.
What ADVATE is and what it is used for 
Kaj je zdravilo ADVATE in za kaj ga uporabljamo
Thrombin then converts fibrinogen into fibrin and a clot can be formed. 
Trombin nato pretvori fibrinogen v fibrin in tako nastane krvni strdek.
Baxter AG Industriestrasse 67 A-1221 Vienna Austria 
Baxter AG Industriestrasse 67 A-1221 Dunaj Avstrija
The table is according to the MedDRA system organ classification (SOC and Preferred Term Level). 
Preglednica je v skladu z razvrstitvijo organskih sistemov MedDRA (raven organskih sistemov in prednostnih izrazov).
Your doctor will calculate your dose of ADVATE (in international units or IU) depending on your condition and body weight, and on whether it is used for prevention or treatment of bleeding. 
Zdravnik vam bo izračunal odmerek zdravila ADVATE (v mednarodnih enotah ali i.e.) glede na vaše stanje in telesno maso ter glede na to, ali zdravilo prejemate za preprečevanje krvavitev ali za njihovo zdravljenje.
Swirl gently until all material is dissolved. 
Vialo nežno obračajte, dokler se vsa vsebina ne raztopi.
Do not use ADVATE - if you are allergic to octocog alfa or any of the other ingredients of this medicine (listed in section 6) - if you are allergic to mouse or hamster proteins 
Ne uporabljajte zdravila ADVATE - če ste alergični na oktokog alfa ali katerokoli sestavino tega zdravila (navedeno v poglavju 6), - če ste alergični na mišje ali hrčkove beljakovine.
The factor VIII/von Willebrand Factor complex consists of two molecules (factor VIII and von Willebrand Factor) with different physiological functions. 
Kompleks faktorja VIII in von Willebrandovega faktorja je sestavljen iz dveh molekul (faktorja VIII in von Willebrandovega faktorja), ki imata različni fiziološki funkciji.
You or someone else might also administer ADVATE as an injection, but only after receiving adequate training. 
Tudi sami si lahko date zdravilo ADVATE z injekcijo oziroma vam jo da kdo drug, vendar šele po ustreznem usposabljanju.
Activated factor VIII acts as a Cofactor for activated Factor IX, accelerating the conversion of Factor X to activated Factor X. Activated Factor X converts prothrombin to thrombin. 
Aktiviran faktor VIII deluje kot kofaktor aktiviranega faktorja IX in pospeši pretvorbo faktorja X v aktiviran faktor X. Aktiviran faktor X pretvori protrombin v trombin.
The solvent vial has a blue stripe. 
Viala z vehiklom ima modro črto.
Pharmacokinetic data with ADVATE on previously untreated patients are currently not available. 
Farmakokinetični podatki za zdravilo ADVATE pri bolnikih, ki predhodno niso bili zdravljeni, trenutno niso na voljo
Your doctor will perform appropriate laboratory tests to make sure that you have adequate Factor VIII levels. 
Zdravnik bo opravil potrebne laboratorijske preiskave za zagotovitev potrebne koncentracije faktorja VIII.
Cleanse stoppers with alcohol swabs. 
Očistite zamaške z alkoholnimi tamponi.
Do not use solutions that are cloudy or have deposits. 
Ne uporabljajte raztopin, ki so motne ali imajo usedlino.
- Any unused medicinal product or waste material should be disposed of in accordance with local requirements. 
- Neuporabljeno zdravilo ali odpadni material zavrzite v skladu z lokalnimi predpisi.
If severe, sudden allergic reactions (anaphylactic) occur, the injection must be stopped immediately. 
Če se pojavijo hude, nenadne alergijske (anafilaktične) reakcije, morate injiciranje zdravila nemudoma ustaviti.